Review
Medicine, Research & Experimental
Mingzhen Zhou, Baorui Liu, Jie Shen
Summary: Hepatocellular carcinoma (HCC) is a common malignancy with late-appearing symptoms, making diagnosis and treatment challenging. Immunotherapy, including immune checkpoint inhibitors, liver cancer vaccines, and cellular therapies, has emerged as a new hope for HCC treatment by regulating the immune system to target liver cancer cells.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Endocrinology & Metabolism
Wenge Dong, Yangyang Xie, Hai Huang
Summary: This study investigated the specific functions of cancer-associated fibroblast (CAF)-related genes in hepatocellular carcinoma (HCC) and found their prognostic significance. Cluster analysis and risk score model were used to identify different risk groups with significant differences in overall survival and chemosensitivity. Furthermore, the study explored the correlation between immune infiltration characteristics and different risk levels. These findings provide possibilities for personalized treatment in HCC.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Immunology
Isabella Lurje, Wiebke Werner, Raphael Mohr, Christoph Roderburg, Frank Tacke, Linda Hammerich
Summary: Hepatocellular Carcinoma (HCC) is a highly prevalent malignancy that arises in patients with chronic liver diseases and dysregulated immunity. In situ vaccines harness the tumor as an antigen source and implement immunomodulation to generate systemic and lasting antitumor immunity, potentially switching the immunosuppressive environment of HCC to an immunostimulatory one.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Fahui Liu, Jiadong Liang, Puze Long, Lilan Zhu, Wanyun Hou, Xueming Wu, Chunying Luo
Summary: This study found that ZCCHC17 is highly expressed in hepatocellular carcinoma (HCC) and is associated with patient prognosis. Functional analysis revealed that ZCCHC17 is mainly involved in immune regulation and is associated with immune cell infiltration in the tumor microenvironment.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Zhiyi Li, Ying Zhang, Baipan Zhang, Rui Guo, Minhua He, Zi-Ling Liu, Lei Yang, Hong Wang
Summary: Hepatocellular carcinoma is a significant global health concern with limited treatment options. Immunotherapy has shown promising advancements in the treatment of this disease, but research focus and trends are evolving.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Shengwei Tao, Shuhang Liang, Taofei Zeng, Dalong Yin
Summary: Hepatocellular carcinoma (HCC) is a deadly form of primary liver cancer. Palliative therapies like multi-tyrosine kinase inhibitors (TKIs) have been the front-line treatment for advanced HCC, but there is limited benefit. Immune checkpoint inhibitors (ICIs) have shown promise in treating unresectable solid tumors, but their effectiveness in HCC is limited. This review explores the role of epigenetic modifications in HCC immune resistance to ICIs and discusses potential epigenetic therapies to overcome immune resistance.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Qiaoyun Liu, Wei Huang, Wenjin Liang, Qifa Ye
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide, with limited clinical diagnosis and treatment options. Research on immune-associated cells in the microenvironment, particularly macrophages, is being undertaken to develop novel effective approaches for HCC. Macrophages play a critical role in phagocytosing tumor cells, presenting tumor-specific antigens, and initiating anticancer immune responses. However, the presence of M2-phenotype tumor-associated macrophages (TAMs) at tumor sites promotes immune evasion, tumor progression, and suppression of tumor-specific T-cell immune responses. Biomaterials offer potential solutions to modulate and target macrophages for enhanced HCC immunotherapy.
Article
Oncology
Qing Yan, Hao-Ming Lin, Ke Zhu, Yi Cao, Xiao-Lin Xu, Zi-Yu Zhou, Lei-bo Xu, Chao Liu, Rui Zhang
Summary: This study evaluated the expression of FGL1 and its association with immune infiltration in hepatocellular carcinoma (HCC). The results showed that FGL1 expression was abnormal in different tumors and correlated with the infiltration level of immune cells. Additionally, FGL1 positive circulating tumor cells were associated with worse prognosis in HCC patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Shuling Chen, Xuezhen Zeng, Tianhong Su, Han Xiao, Manxia Lin, Zhenwei Peng, Sui Peng, Ming Kuang
Summary: Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide, and local ablation is an effective treatment method. However, high recurrence rates remain a challenge. Studies have shown that ablation can modulate tumor signaling pathways and the immune microenvironment, inducing tumor-specific immune responses. Immunotherapies have the potential to enhance the anti-tumor immune response induced by ablation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Catia Giovannini, Fabrizia Suzzi, Francesco Tovoli, Mariangela Bruccoleri, Mariarosaria Marseglia, Eleonora Alimenti, Francesca Fornari, Massimo Iavarone, Fabio Piscaglia, Laura Gramantieri
Summary: By using a simple cytofluorimetric test on peripheral blood, we discovered that patients with a low baseline PD1+ granulocyte percentage are more likely to benefit from atezolizumab-bevacizumab treatment. These findings need to be validated in larger cohorts to determine the potential use of this test in clinical practice.
Review
Oncology
Muhammet Ozer, Suleyman Yasin Goksu, Baran Akagunduz, Andrew George, Ilyas Sahin
Summary: Immunotherapy is the standard treatment for advanced hepatocellular carcinoma (HCC), but drug resistance is a limitation. This review discusses adoptive cell therapy (ACT) as an emerging cancer therapy for HCC and provides a summary of ongoing clinical trials.
Article
Oncology
Jianye Wang, Ying Wang, Marcella Steffani, Christian Stoess, Donna Ankerst, Helmut Friess, Norbert Hueser, Daniel Hartmann
Summary: Pyroptosis plays an important role in cancer development and immune response, but the specific roles of pyroptosis-related genes in tumor progression, immune response, prognosis, and immunotherapy have not been fully elucidated. Through clustering analysis, three distinct molecular subtypes related to pyroptosis were identified in hepatocellular carcinoma, and these subtypes had differential prognostic effects on patient survival. Immune characteristics analysis revealed diverse immune cell infiltration among the subtypes.
Review
Immunology
Rohini Sharma, Leila Motedayen Aval
Summary: The treatment landscape for hepatocellular cancer (HCC) has shifted with the introduction of immune checkpoint inhibitors (ICIs) showing potential for improved survival in first-line treatment. However, response rates to ICIs are limited and patients will still progress. The optimal second-line therapies following exposure to ICIs remain unclear.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, Giorgio Frega, Andrea Palloni, Simona Tavolari, Giovanni Brandi
Summary: Immune checkpoint inhibitors, particularly the combination of PD-L1 inhibitor and antiangiogenic agent, have emerged as novel systemic treatment options for advanced HCC. Despite this, reliable predictors of response to immunotherapy in HCC patients remain unanswered questions.
FRONTIERS IN ONCOLOGY
(2021)
Review
Endocrinology & Metabolism
Guizhen Zhang, Guanchang Ji, Liwen Liu, Huifen Wang, Zhigang Ren, Ranran Sun, Zujiang Yu
Summary: Hepatocellular carcinoma (HCC) is the major subtype of liver cancer and ranks sixth in cancer incidence and third in mortality. The tumor immune microenvironment (TME) plays a significant role in the development of HCC and affects the efficacy of HCC treatment. Although Chimeric Antigen Receptor-Modified T (CAR-T) cell therapy has shown promise in hematological malignancies, its effectiveness is compromised in solid tumors like HCC due to a hostile TME.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Gastroenterology & Hepatology
Nathalie Schmidt, Robert Thimme
DIGESTIVE DISEASES
(2016)
Meeting Abstract
Gastroenterology & Hepatology
N. Schmidt, L. J. Pallett, A. Schurich, K. Suveizdyte, O. E. Amin, F. Froghi, B. R. Davidson, R. Gillmore, T. Meyer, W. Rosenberg, M. Maini
JOURNAL OF HEPATOLOGY
(2018)
Article
Immunology
Nicholas J. W. Easom, Kerstin A. Stegmann, Leo Swadling, Laura J. Pallett, Alice R. Burton, Dennis Odera, Nathalie Schmidt, Wei-Chen Huang, Giuseppe Fusai, Brian Davidson, Mala K. Maini
FRONTIERS IN IMMUNOLOGY
(2018)
Review
Medicine, General & Internal
N. Schmidt, N. Buettner, R. Thimme
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
(2013)
Article
Gastroenterology & Hepatology
Tobias Flecken, Nathalie Schmidt, Sandra Hild, Emma Gostick, Oliver Drognitz, Robert Zeiser, Peter Schemmer, Helge Bruns, Thomas Eiermann, David A. Price, Hubert E. Blum, Christoph Neumann-Haefelin, Robert Thimme
Editorial Material
Oncology
Nathalie Schmidt, Tobias Flecken, Robert Thimme
Review
Immunology
L. J. Pallett, N. Schmidt, A. Schurich
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2019)
Article
Cell Biology
Leo Swadling, Laura J. Pallett, Mariana O. Diniz, Josephine M. Baker, Oliver E. Amin, Kerstin A. Stegmann, Alice R. Burton, Nathalie M. Schmidt, Anna Jeffery-Smith, Nekisa Zakeri, Kornelija Suveizdyte, Farid Froghi, Giuseppe Fusai, William M. Rosenberg, Brian R. Davidson, Anna Schurich, A. Katharina Simon, Mala K. Maini
Article
Immunology
Laura J. Pallett, Alice R. Burton, Oliver E. Amin, Sergio Rodriguez-Tajes, Amit A. Patel, Nekisa Zakeri, Anna Jeffery-Smith, Leo Swadling, Nathalie M. Schmidt, Anna Baiges, Amir Gander, Dominic Yu, David Nasralla, Farid Froghi, Satheesh Iype, Brian R. Davidson, Douglas Thorburn, Simon Yona, Xavier Forns, Mala K. Maini
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Article
Immunology
Catherine J. Reynolds, Leo Swadling, Joseph M. Gibbons, Corinna Pade, Melanie P. Jensen, Mariana O. Diniz, Nathalie M. Schmidt, David K. Butler, Oliver E. Amin, Sasha N. L. Bailey, Sam M. Murray, Franziska P. Pieper, Stephen Taylor, Jessica Jones, Meleri Jones, Wing-Yiu Jason Lee, Joshua Rosenheim, Aneesh Chandran, George Joy, Cecilia Di Genova, Nigel Temperton, Jonathan Lambourne, Teresa Cutino-Moguel, Mervyn Andiapen, Marianna Fontana, Angelique Smit, Amanda Semper, Ben O'Brien, Benjamin Chain, Tim Brooks, Charlotte Manisty, Thomas Treibel, James C. Moon, Mahdad Noursadeghi, Daniel M. Altmann, Mala K. Maini, Aine McKnight, Rosemary J. Boyton
SCIENCE IMMUNOLOGY
(2020)
Article
Multidisciplinary Sciences
Catherine J. Reynolds, Corinna Pade, Joseph M. Gibbons, David K. Butler, Ashley D. Otter, Katia Menacho, Marianna Fontana, Angelique Smit, Jane E. Sackville-West, Teresa Cutino-Moguel, Mala K. Maini, Benjamin Chain, Mahdad Noursadeghi, Tim Brooks, Amanda Semper, Charlotte Manisty, Thomas A. Treibel, James C. Moon, Ana M. Valdes, Aine McKnight, Daniel M. Altmann, Rosemary Boyton
Summary: Vaccination with a single dose of BNT162b2 after prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants. In contrast, individuals without prior infection showed reduced immunity against variants after receiving a single vaccine dose.
Article
Multidisciplinary Sciences
Nathalie M. Schmidt, Peter A. C. Wing, Mariana O. Diniz, Laura J. Pallett, Leo Swadling, James M. Harris, Alice R. Burton, Anna Jeffery-Smith, Nekisa Zakeri, Oliver E. Amin, Stephanie Kucykowicz, Mirjam H. Heemskerk, Brian Davidson, Tim Meyer, Joe Grove, Hans J. Stauss, Ines Pineda-Torra, Clare Jolly, Elizabeth C. Jury, Jane A. McKeating, Mala K. Maini
Summary: This study demonstrates that targeting cholesterol esterification can inhibit hepatitis B virus in vitro, while enhancing exhausted antigen-specific T cell responses from human liver and hepatocellular carcinoma.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Leo Swadling, Mariana O. Diniz, Nathalie M. Schmidt, Oliver E. Amin, Aneesh Chandran, Emily Shaw, Corinna Pade, Joseph M. Gibbons, Nina Le Bert, Anthony T. Tan, Anna Jeffery-Smith, Cedric C. S. Tan, Christine Y. L. Tham, Stephanie Kucykowicz, Gloryanne Aidoo-Micah, Joshua Rosenheim, Jessica Davies, Marina Johnson, Melanie P. Jensen, George Joy, Laura E. McCoy, Ana M. Valdes, Benjamin M. Chain, David Goldblatt, Daniel M. Altmann, Rosemary J. Boyton, Charlotte Manisty, Thomas A. Treibel, James C. Moon, Lucy van Dorp, Francois Balloux, Aine McKnight, Mahdad Noursadeghi, Antonio Bertoletti, Mala K. Maini
Summary: Research suggests that some individuals can clear potential SARS-CoV-2 infection after exposure, with T cells playing a role in the process. Studying healthcare workers who tested negative for antibodies revealed that they had stronger and more diverse memory T cells, with a focus on RTC.
Article
Multidisciplinary Sciences
Nekisa Zakeri, Andrew Hal, Leo Swadling, Laura J. Pallett, Nathalie M. Schmidt, Mariana O. Diniz, Stephanie Kucykowicz, Oliver E. Amin, Amir Gander, Massimo Pinzani, Brian R. Davidson, Alberto Quaglia, Mala K. Maini
Summary: This study suggests that boosting T-cells with tissue-resident memory T-cells (T-RM) may improve the response to immunotherapy for advanced hepatocellular carcinoma (HCC). Higher frequencies of gamma delta T-cells, which exhibit tissue-residency and superior anti-tumour cytokine production, are associated with enhanced patient survival. Aminobisphosphonate-based expansion of V gamma 9V delta 2T cells can potentially replenish the depleted pool and enhance cytotoxic potential, making it a promising approach for HCC immunotherapy.
NATURE COMMUNICATIONS
(2022)